| 0.219 -0.031 (-12.4%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.58  |
1-year : | 4.02 |
| Resists | First : | 2.21 |
Second : | 3.45 |
| Pivot price | 1.16 |
|||
| Supports | First : | 0.2 |
Second : | 0.17 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 1.59 |
| MA(100) : | 8.22 |
MA(250) : | 297.89 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 0.5 |
D(3) : | 0.6 |
| RSI | RSI(14): 17.5 |
|||
| 52-week | High : | 2360 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDT ] has closed above bottom band by 17.1%. Bollinger Bands are 70.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 103 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.23 - 0.23 | 0.23 - 0.23 |
| Low: | 0.2 - 0.21 | 0.21 - 0.21 |
| Close: | 0.22 - 0.22 | 0.22 - 0.22 |
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Mon, 14 Sep 2026
What Put CDT Equity (CDT) on the Market Radar? - Kalkine Media
Fri, 11 Sep 2026
Premarket Movers September 11, 2026: TNONW and TNON Lead Gainers, CDT and KPTI Lead Losers - ChartMill
Thu, 10 Sep 2026
Premarket movers Sept. 10, 2026: TNONW, TNON among gainers; CDT, MGN among losers - ChartMill
Wed, 09 Sep 2026
One investor now owns 9.6% of CDT Equity (CDT). The disclosure names who. - Stock Titan
Fri, 04 Sep 2026
CDT Equity Amends $8 Million Sarborg Investment and Adds $542K Convertible Note, Later Repaid - TradingView
Wed, 02 Sep 2026
CDT Equity Names James Bligh CEO Amid Leadership Shift - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 712810 (%) |
| Held by Institutions | 51.9 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -69.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57448e+007 |
| Qtrly Earnings Growth | 50.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 9950 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|